Abcam, ab318933, Human Acetylcholinesterase ELISA Kit - Intracellular

Size: 1 x 96Tests / 1 x 384Tests / 10 x 96Tests
Human Acetylcholinesterase ELISA Kit - Intracellular is a single-wash 90-min Simplestep used to quantify Human Acetylcholinesterase with a sensitivity of 23.392 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Different formats for different needs: 10x96 plates for bulk orders and 384-well plate for higher throughput
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate, Tissue Extracts,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 23.392 pg/mL,
Range:46.875 - 3000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human Acetylcholinesterase SimpleStep ELISA® kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Acetylcholinesterase protein in Cell Lysate, Tissue extracts. Quantitate Human Acetylcholinesterase with 23.392 pg/ml sensitivity.
SimpleStep ELISA
technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA
plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA
protocol summary in the image section for further details. Our SimpleStep ELISA
technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips, available in 10-pack (10 x 96-well plates)
-Also available in a fully validated 384-well format.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Acetylcholinesterase also known as AChE is an enzyme with a molecular mass of approximately 67 kDa. It plays a critical role in neurotransmission by catalyzing the hydrolysis of the neurotransmitter acetylcholine into acetate and choline. This reaction occurs at neuromuscular junctions and cholinergic synapses therefore terminating synaptic transmission. AChE is highly expressed in muscle and brain tissue particularly in the synaptic cleft where it regulates the nerve signal terminations.
Biological function summary
Acetylcholinesterase is essential for maintaining neurotransmission dynamics by ensuring timely acetylcholine breakdown. It does not function as part of a larger enzyme complex but its activity is necessary for efficient synaptic signaling in the nervous system. This enzymatic action prevents continuous stimulation of muscles and nerves by rapidly degrading acetylcholine thereby ensuring proper muscle contraction and cognitive processes.
Pathways
Acetylcholinesterase participates significantly in the cholinergic system. It influences cholinergic signaling pathways by inactivating acetylcholine after its release into the synaptic cleft. This function aligns acetylcholinesterase closely with receptors like nicotinic and muscarinic acetylcholine receptors. It indirectly affects signal transduction pathways that involve these receptors with potential downstream effects on ion channels and intracellular messengers.
Acetylcholinesterase plays a significant role in Alzheimer's disease and myasthenia gravis. In Alzheimer's disease decreased acetylcholinesterase function can lead to accumulations of acetylcholine and disrupted signaling contributing to cognitive dysfunction. Acetylcholinesterase inhibitors are therapeutic in such contexts. For myasthenia gravis a disorder affecting neuromuscular transmission the enzyme’s interaction with antibodies targets synaptic acetylcholine receptors. This interaction results in weakened muscle contractions correlating with condition severity.